A Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose Study of the Safety, Tolerability, and Pharmacokinetics of Intravenously or Subcutaneously Administered REGN5069 in Healthy Volunteers
Phase of Trial: Phase I
Latest Information Update: 27 Nov 2019
Price : $35 *
At a glance
- Drugs REGN-5069 (Primary) ; REGN-5069 (Primary)
- Indications Pain
- Focus Adverse reactions
- Sponsors Regeneron Pharmaceuticals
- 25 Nov 2019 Status changed from active, no longer recruiting to completed.
- 17 Jul 2019 Planned End Date changed from 10 May 2019 to 27 Sep 2019.
- 17 Jul 2019 Planned primary completion date changed from 10 May 2019 to 27 Sep 2019.